Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 11Phase 4 6Phase NA 4Phase 1 3

Status

Completed 6Terminated 2Recruiting 2

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Endocrine 3NET 2Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Acromegaly 2Pituitary Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Cisplatin 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × Completed × Octreotide × Clear all
NCT03289741 2025-05-09

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Center

Phase 4 Completed
51 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

NCT05682209 2023-01-18

The Effect of Octreotide on Wound Drainage After Mastectomy

University College Hospital, Ibadan

Phase 4 Completed
41 enrolled
Breast

Breast Neoplasms

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Novartis

Phase 4 Completed
20 enrolled

Acromegaly

NCT00050635 2009-11-19

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Novartis

Phase 4 Completed
150 enrolled
Gastrointestinal

Diarrhea, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡